Nuvama Wealth Management approves 79.3 lakh ESARs for employees
- NRC approved 79,38,556 ESARs for employees on September 1, 2026
- 73,93,366 ESARs vest over five years; 5,45,190 over four years
- Rights exercisable within two years post-vesting
- Pricing based on market closing price prior to grant date

*this image is generated using AI for illustrative purposes only.
Nuvama Wealth Management approved the grant of 79,38,556 Employee Stock Appreciation Rights (ESARs) to eligible employees on September 1, 2026. The Nomination and Remuneration Committee (NRC) sanctioned the grants under the company’s 2026 ESAR scheme.
The decision aligns with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company disclosed the details to the BSE and NSE on the same day.
Grant Structure and Vesting
The total grant comprises 79,38,556 ESARs. The vesting schedule is split into two distinct tranches based on employee eligibility:
- 73,93,366 ESARs will vest in annual tranches over five years.
- 5,45,190 ESARs will vest in equal annual tranches over four years.
Employees have two years from the date of vesting to exercise these rights. The settlement of appreciated value occurs through equity shares upon payment of the exercise price and applicable taxes.
Pricing Mechanism
The ESAR price equals the market price of the shares on the date immediately prior to the grant date. Market price is defined as the closing price on the recognized stock exchange with higher trading volume if listed on multiple exchanges.
What the Numbers Show
The majority of the grant (73,93,366 out of 79,38,556) is tied to a longer five-year vesting period. This structure suggests a focus on long-term retention for the bulk of eligible employees, while a smaller cohort (5,45,190 ESARs) benefits from a slightly accelerated four-year timeline.
Historical Stock Returns for Nuvama Wealth Management
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +1.79% | +2.00% | -1.04% | +43.39% | +39.80% | 0.0% |
How might the dilution from the eventual exercise of nearly 8 million ESARs impact Nuvama Wealth Management's earnings per share (EPS) over the next five years?
What does the split between four-year and five-year vesting schedules indicate about the company's retention strategy for senior leadership versus broader employee cohorts?
How will the settlement of these ESARs through equity shares affect the company's cash flow compared to a cash-settled appreciation rights scheme?


































